{
}
Barclays has upgraded Natera's stock rating to Overweight with a $200 price target, citing the company's impressive 158% return over the past year and its successful expansion into new markets, particularly in NIPT and MRD testing. Natera reported a record Q3 revenue of $439.8 million, a 64% increase from the previous year, and is gaining market share in Organ Health. Despite a setback in a lawsuit against Guardant Health, Natera's management remains confident in sustaining growth through its own capabilities.
Barclays has initiated coverage of Guardant Health with an Overweight rating and a price target of $60, citing strong revenue growth of 29.2% and positive developments in MRD surveillance coverage. The stock has surged 26.5% recently, nearing its 52-week high, and analysts expect continued growth driven by advancements in cancer diagnostics and expanded Medicare coverage for its tests. Guardant Health's market capitalization stands at $5.83 billion, with a focus on personalized cancer treatment through innovative liquid biopsy technology.
Guardant Health, a precision oncology company, has seen significant activity from institutional investors, who now own 92.60% of its stock. Recent earnings revealed a revenue increase of 33.9% year-over-year, despite a loss of $0.88 per share, missing estimates. Analysts maintain a "Buy" rating, with a consensus price target of $41.81, while insiders have recently sold shares, indicating mixed signals about the company's future.
Barclays has initiated coverage on Guardant Health with an Overweight rating and a price target of $60, citing strong revenue growth of 29.2% and positive developments in MRD surveillance. The stock has surged 26.5% recently, nearing its 52-week high, and analysts expect continued growth driven by advancements in cancer diagnostics and expanded Medicare coverage for its tests. Guardant Health's market capitalization stands at $5.83 billion, with a focus on personalized oncology solutions.
UBS has reiterated a Buy rating on Guardant Health, maintaining a $40 price target and naming it a top pick in Life Sciences & Diagnostic Tools. Analyst Dan Leonard highlighted the promising potential of the Shield test for colorectal cancer screening, with anticipated revenue growth and expanded Medicare reimbursement for the Reveal test expected in 2025. Guardant Health's recent partnership with Boehringer Ingelheim and impressive 29.2% revenue growth over the past year further bolster its positive outlook.
UBS has reiterated a Buy rating on Guardant Health, maintaining a $40 price target and naming it a top pick in Life Sciences & Diagnostic Tools. Analyst Dan Leonard highlighted the promising potential of the Shield test for colorectal cancer screening, with anticipated revenue growth and expanded Medicare reimbursement for the Reveal test expected in 2025. Guardant Health reported a 29.2% revenue increase over the past year and is set to disclose Shield test volumes in its upcoming fourth-quarter results on February 20, 2025.
Guardant Health, Inc. is a precision oncology company that specializes in blood and tissue tests, offering a range of products including the Guardant360 suite and the GuardantOMNI Test for advanced cancer stages. The company also provides integrated software solutions for clinical and biopharmaceutical clients, alongside development services for companion diagnostics. Founded in 2011 and based in Palo Alto, California, Guardant Health collaborates with Illumina, Inc. to enhance cancer research through specimen sample sharing.
Guardant Health, Inc.
Companies
| Symbol | GH |
| Name | Guardant Health, Inc. |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Market | NASDAQ Global Select |
| Country | United States |
| State | CA |
| City | Redwood City |
| Zipcode | 94063 |
| Website | http://guardanthealth.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Barclays upgrades Natera stock to Overweight with $200 price target
15:13 23.01.2025
Barclays assigns Overweight rating to Guardant Health with $60 price target
United States Dollar
Guardant Health, Inc.
Boehringer Ingelheim KG
Barclays PLC
USA
Luke Sergott
Show more
15:09 23.01.2025
guardant health sees increased institutional investment and analyst ratings
JPMorgan Chase & Co.
Leerink Partners LLC
Wexford Capital LP
Mirae Asset Global Investments Co. Ltd. - Mirae Asset Tiger Global Artificial Intelligence & Robotic
Guggenheim High Yield P
Sanford C. Bernstein Fund, Inc. - Tax-Aware Overlay B Portfolio
The Goldman Sachs Group, Inc.
Guardant Health, Inc.
Barclays PLC
USA
Musa Tariq
Meghan Joyce
Show more
14:42 23.01.2025
barclays assigns overweight rating to guardant health with price target of sixty dollars
14:38 23.01.2025
ubs names guardant health top pick with maintained price target of 40
22:39 10.01.2025
ubs names guardant health top pick with maintained price target of forty dollars
22:00 10.01.2025
guardant health advances precision oncology with innovative blood and tissue tests
00:00 26.11.2024
Trending
Subcategory
Corporate News
Industry Trends
Stock Market Updates
Finance Mergers & Acquisitions
Retail and Consumer Goods
Global Financial Events
Global Trade Developments
Industry Mergers & Acquisitions
Banking Regulations
CEO Changes
Market Analysis and Predictions
Supply Chain Management
Workplace Trends
Government Economic Policies
Central Bank Actions
Startups & Entrepreneurship
Hedge Funds & Private Equity
Financial Scams and Security
Government Policies
Domestic Politics
Countries:
Companies:
Barclays PLC
BNP Paribas SA
Tesla, Inc.
Deutsche Bank RV Global PP
Apple Inc.
Raiffeisen Bank International AG
JPMorgan Chase & Co.
Citigroup Inc.
UniCredit S.p.A.
Strabag SE
The Goldman Sachs Group, Inc.
UBS Group AG
Bank of America Corporation
Google Inc.
Morgan Stanley
Kering S.A. (ADRs)
Banco BPM S.p.A.
Berner Kantonalbank AG
Microsoft Corporation
Lloyds Banking Group plc
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Indian Rupee
Japanese Yen
Vietnamese Đồng
Hong Kong Dollar
United Arab Emirates Dirham
Australian Dollar
Indonesian Rupiah
Russian Ruble
Brazilian Real
Filipino Peso
Malaysian Ringgit
South African Rand
South Korean Won
Offshore Chinese Yuan
Ghanaian Cedi
People: